Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 14/20 | 0.54 |
| ▸ | HTR1B | P28222 | 1/20 | 0.47 |
| ▸ | CX3CR1 | P49238 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.38 |
| ▸ | TOP2A | P11388 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3860775 | 0.89 | CXCR2 (0.66) | CXCR2 | |
| SCHEMBL3854052 | 0.88 | CXCR2 (0.54) | CXCR2HTR1BCX3CR1MAPTALDH1A1 | |
| SCHEMBL3852535 | 0.82 | CXCR2 (0.60) | CXCR2HTR1BCX3CR1 | |
| SCHEMBL3860305 | 0.82 | CXCR2 (0.69) | CXCR2HTR1BCX3CR1 | |
| SCHEMBL3917570 | 0.80 | CXCR2 (0.70) | CXCR2HTR1BCX3CR1 | |
| SCHEMBL3857980 | 0.80 | CXCR2 (0.84) | CXCR2HTR1BCX3CR1 | |
| SCHEMBL3854454 | 0.80 | CXCR2 (0.70) | CXCR2HTR1BCX3CR1 | |
| SCHEMBL7515242 | 0.80 | CXCR2 (0.61) | CXCR2HTR1BCX3CR1 | |
| SCHEMBL3870493 | 0.78 | CXCR2 (0.53) | CXCR2HTR1BCX3CR1MAPTALDH1A1 | |
| SCHEMBL6343828 | 0.78 | CXCR2 (0.67) | CXCR2CX3CR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7579342-B2 | Pteridine compounds for the treatment of psoriasis | ASTRAZENECA (SE) | 2009-08-25 | — | — | US | disclosed |
| US-20050171345-A1 | Pteridine compounds for the treatment of psoriasis | ASTRAZENECA AB, A SWEDEN CORPORATION | 2005-08-04 | — | — | US | disclosed |
| US-6875868-B2 | Pteridine compounds for the treatment of psoriasis | ASTRAZENECA AB (SE) | 2005-04-05 | — | — | US | disclosed |
| EP-1259512-B1 | PTERIDINE COMPOUNDS FOR THE TREATMENT OF PSORIASIS | ASTRAZENECA AB (SE) | 2003-09-24 | — | — | EP | disclosed |
| US-20030055250-A1 | Pteridine compounds for the treatment of psoriasis | ASTRAZENECA AB (SE) | 2003-03-20 | — | — | US | disclosed |
| EP-1259512-A1 | PTERIDINE COMPOUNDS FOR THE TREATMENT OF PSORIASIS | AstraZeneca AB (SE) | 2002-11-27 | — | — | EP | disclosed |
| WO-2001062758-A1 | PTERIDINE COMPOUNDS FOR THE TREATMENT OF PSORIASIS | ASTRAZENECA AB (SE) | 2001-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055250-A1 | Pteridine compounds for the treatment of psoriasis | DHFR, NAMPT, HPRT1 | CXCR2 1307/4885HTR1B 2770/4885CX3CR1 1991/4885 |
| US-20050171345-A1 | Pteridine compounds for the treatment of psoriasis | DHFR, NAMPT, HPRT1 | CXCR2 1307/4885HTR1B 2770/4885CX3CR1 1991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.